Search Results - "Sahmoud, T."

Anastrozole Alone or in combination with Tamoxifen versus Tamoxifen Alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in combination) trial efficacy and safety update analyses by Baum, M, Buzdar, A, Cuzick, J, Forbes, J, Houghton, J, Howell, A, Sahmoud, T

“…The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine…”
Get full text

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial by Baum, M, Budzar, A U, Cuzick, J, Forbes, J, Houghton, J H, Klijn, J G M, Sahmoud, T

“…In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, it is associated with…”
Get full text

Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial by Lefebvre, Jean-Louis, Chevalier, Dominique, Luboinski, Bernard, Kirkpatrick, Anne, Collette, Laurence, Sahmoud, Tarek

“…Background: As a general rule, surgery whenever possible, followed by irradiation is considered to be the standard treatment for cancer of the hypopharynx,…”
Get full text

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience by Curran, D, Sahmoud, T, Therasse, P, van Meerbeeck, J, Postmus, P E, Giaccone, G

“…Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data. From October 1984 to…”
Get more information

Characterization of Novel Oral Splicing Modulator, H3B-8800, Identifies the Mechanistic Basis for its Preferential Lethality Towards Spliceosome-Mutant Myeloid Malignancy Models by Buonamici, S, Yoshimi, A, Thomas, M, Seiler, M, Chan, B, Csibi, A, Fekkes, P, Klimek, V, Kumar, P, Lee, S.C.W, Padron, E, Pazolli, E, Goldberg, J, Sahmoud, T, Taylor, J, Warmuth, M, Yu, L, Zhu, P, Abdel-Wahab, O, Smith, P

Get full text

3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial by Gnant, M, Hortobagyi, G.N, Rugo, H, Burris, H.A, Noguchi, S, Pritchard, K.I, Baselga, J, Sahmoud, T, Bauly, H, Piccart, M

Get full text

12 Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial by Gnant, M, Hortobagyi, G.N, Rugo, H, Burris, H.A, Noguchi, S, Pritchard, K.I, Baselga, J, Sahmoud, T, Bauly, H, Piccart, M

Get full text

253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial by Rugo, H, Pritchard, K.I, Gnant, M, Noguchi, S, Piccart, M, Hortobagyi, G.N, Burris, H.A, Bauly, H, Sahmoud, T

Get full text

PCN98 Health Outcome Gains and Costs Offset Associated With Everolimus for the Treatment of Hormone-Receptor–Positive (HR+) HER2-Negative (HER2–) Advanced Breast Cancer (ABC) by Taylor, M, Lewis, L, Vieira, J, Ricci, J.F, Chandiwana, D, Saletan, S, Sahmoud, T

Get full text

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer by Bleiberg, H, Conroy, T, Paillot, B, Lacave, A.J, Blijham, G, Jacob, J.H, Bedenne, L, Namer, M, De Besi, P, Gay, F, Collette, L, Sahmoud, T

“…Patients with measurable or evaluable locally advanced or metastatic squamous cell carcinoma of the oesophagus were treated with cisplatin (CDDP), 100 mg/m 2,…”
Get full text

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer by Clahsen, P C, van de Velde, C J, Duval, C, Pallud, C, Mandard, A M, Delobelle-Deroide, A, van den Broek, L, Sahmoud, T M, van de Vijver, M J

“…Thirty percent of women with node-negative breast cancer will have a recurrence within 10 years after diagnosis. Molecular markers may identify those patients…”
Get more information

Everolimus in Subependymal Giant Cell Astrocytomas (SEGA) Associated with Tuberous Sclerosis Complex (TSC): Results of EXIST-1, a Double-Blind Placebo-controlled Phase III Trial by Bebin, M, Franz, D.N, Sahmoud, T, Belousova, E, Sparagana, S, Frost, M, Ford, J, Shah, G, Cauwel, H, Jozwiak, S

Get full text

Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial by Baselqa, J, Campone, M, Sahmoud, T, Piccart, M, Burris, H, Rugo, H, Noguchi, S, Gnant, M, Mukhopadhyay, P, Hortobagyi, G

Get full text

Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial by Grimaldi, C, Bleiberg, H, Gay, F, Messner, M, Rougier, P, Kok, T C, Cirera, L, Cervantes, A, De Greve, J, Paillot, B, Buset, M, Nitti, D, Sahmoud, T, Duez, N, Wils, J

“…The aim of the study was to evaluate the efficacy of antiandrogen therapy on overall survival and response in unresectable hepatocellular carcinoma (HCC). A…”
Get more information

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group by Giaccone, G, Ardizzoni, A, Kirkpatrick, A, Clerico, M, Sahmoud, T, van Zandwijk, N

“…Thymomas are rare neoplasms of the mediastinum. The role of chemotherapy in advanced thymomas is not fully established. In the European Organization for…”
Get more information

Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study by Gregor, A, Drings, P, Burghouts, J, Postmus, P E, Morgan, D, Sahmoud, T, Kirkpatrick, A, Dalesio, O, Giaccone, G

“…To evaluate the effectiveness of alternating or sequential schedules of cyclophosphamide, doxorubicin, and etoposide (CDE) chemotherapy and irradiation in…”
Get more information

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab by Jerusalem, G. H., Dieras, V., Cardoso, F., Bergh, J., Fasolo, A., Rorive, A., Manlius, C., Pylvaenaeinen, I., Sahmoud, T., Gianni, L.

“…Abstract only…”
Get full text

Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer by ANDERSON, T. J, DIXON, J. M, STUART, M, SAHMOUD, T, MILLER, W. R

“…Anastrozole is an orally active, non-steroidal aromatase inhibitor which appears effective as neoadjuvant treatment of breast cancer. Histological changes have…”
Get full text

Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer by MILLER, W. R, STUART, M, SAHMOUD, T, DIXON, J. M

“…The effect of anastrozole on peripheral and tumour aromatase activity and oestrogen levels in postmenopausal patients with oestrogen receptor-rich breast…”
Get full text

Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer by Amaud, J. P., Nordlinger, B., Bosset, J. F., Hoctinboes, G., Sahmoud, T., Schlag, P. M., Peney, F.

“…Background There is controversy whether adjuvant radiotherapy should be given before or after surgery for locally advanced, resectable rectal cancer…”
Get full text